Vifor Pharma

Vifor Pharma AG, a pharmaceutical company, focuses on the development, manufacture, and commercialization of pharmaceutical products in Switzerland, rest of Europe, the United States, and internationally. The company offers Ferinject/Injectafer, a solution of ferric carboxymaltose used for the treatment of iron deficiency and iron deficiency anemia; Maltofer, an oral iron polymaltose complex for infants, children, adolescents, and pregnant woman with iron deficiency; and Mircera, a long-acting erythropoiesis-stimulating agent (ESA) to treat symptomatic anemia associated with the chronic kidney disease (CKD).It also provides Retacrit, a short-acting ESA; Venofer, an intravenous iron sucrose used in the intravenous treatment of iron deficiency; and Velphoro, a non-calcium, iron-based chewable phosphate binder for the treatment of hyperphosphatemia in adults with CKD undergoing dialysis. In addition, the company offers Rayaldee, an orally administered, extended release formulation of calcifediol for the treatment of secondary hyperparathyroidism in patients with CKD; and Veltassa for the treatment of hyperkalemia in CKD and chronic heart failure patients. Further, it develops Vadadustat, an investigational oral hypoxia-inducible factor prolyl hydroxylase inhibitor for the treatment of altitude on oxygen availability; Avacopan, an orally-administered, highly selective inhibitor of C5aR1 for the treatment of orphan and rare renal diseases;ANG-3777 for the treatment of transplant-associated acute kidney injury; Difelikefalin for the treatment for chronic kidney disease-associated pruritus; and VIT-2763 to treat beta-thalassemia. Vifor Pharma AG has a strategic partnership with Fresenius Kabi and Zeria Pharmaceutical. The company was founded in 1872 and is headquartered in Sankt Gallen, Switzerland. As of August 9, 2022, Vifor Pharma AG operates as a subsidiary of CSL Behring AG.

In 1872, Caspar Friedrich Hausmann founds a pharmacy in St. Gallen

In 1927, 16 pharmacists establish a joint purchasing centre, Collaboration Pharmaceutique SA, which went on to be renamed Galenica AG in 1933

In 1944, The pharmacist René Grosclaude founds Vifor Ltd; the company produces over-the-counter medicines

In 1983, Hausmann AG laboratories is acquired by Galenica

In 1991, Vifor Ltd. is founded and takes over the work of Laboratorien Hausmann in developing new iron products

In 2008, Vifor Pharma is founded following the $915 million acquisition of a Canadian company, Aspreva Pharmaceutical Corporation, Vifor Ltd. and Vifor Ltd. are integrated in Vifor Pharma.

In 2009, Galenica acquires OM Pharma, a Swiss biotechnology company

In 2010, Vifor Pharma Group and Fresenius Medical Care found the joint company Vifor Fresenius Medical Care Renal Pharma

In 2014, Galenica is divided into two divisions, Vifor Pharma and Galenica Santé

In 2016, Relypsa, a US based biotechnology company, is purchased for $1.53 billion

In 2017, the IPO of Galenica Santé is completed and listed on the Swiss Stock Exchange. Galenica AG and Vifor Pharma AG are listed as independent entities since

In 2018, the US Food and Drug Administration FDA approved a Supplemental New Drug Application for the potassium binder Veltassa with or without food

In 2019, Vifor Fresenius Medical Care Renal Pharma received the Swiss Success Award from the non-profit organisation Swiss Biotech Association

In 2020, Vifor Pharma sells 100% of OM Pharma to Optimus Holding Limited for CHF 435 million

In 2020, Vifor Pharma also forms a Joint Venture agreement with Fresenius Kabi for the market in the People's Republic of China in the area of intravenous iron deficiency treatments

In the same year, a deal with Cara Therapeutics for the commercialisation of Difelikefalin to treat CKD-aP patients has been signed.

In 2021 Vifor Pharma concluded a licensing agreement for the commercialisation of sparsentan in Europe, Australia, and New Zealand.

In the same year, Tavneos was approved in the US, Japan and the EU. Korsuva / Kapruvia reached approval in the United States and the EU.

In November 2021, Vifor Pharma Group acquired Sanifit with its novel inhibitor of vascular calcification SNF472 for the treatment of calcific uremic arteriolopathy and peripheral artery disease in patients with end-stage kidney disease. On the same day, Vifor announced the acquisition of Swiss-based Inositec who develops treatments for soft tissue and vascular calcification disorders and aortic valve stenosis .

In December 2021 CSL Limited announced it would acquire Vifor Pharma for CHF 10.9 billion . The capital raising is considered one of the ten largest secondary-market deals worldwide in 2021.

In August 2022 the acquisition of Vifor Pharma by Australian company CSL was completed. Vifor Pharma became CSL Vifor.

Vifor Pharma’s mission is to improve the lives of patients with iron deficiency and other related conditions. By pushing the boundaries of science, our aim is to use innovative solutions and superior quality to benefit people who depend on our products.

Vifor Pharma’s vision is to become the global leader in researching, developing and commercializing innovative treatments for iron deficiency and other related conditions. We strive to be at the forefront of scientific advances and to provide a superior and accessible healthcare experience to our patients around the world.